Evidence map›Paper›PMID 40651990›Full record

ArticleScientific reports2025

Nomogram construction and survival analysis in T3N0M0 breast cancer: a SEER population-based analysis.

Lizhi Teng, Zeyu Zhang, Juntong Du, Yuhan Dong, Weiyang Tao

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lizhi TengDepartment of Breast Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Zeyu ZhangDepartment of Anesthesiology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Juntong DuDepartment of Breast Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Yuhan DongDepartment of Breast Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Weiyang TaoDepartment of Breast Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China. twyssci@outlook.com.

Funding

BEIJING MEDICAL AWARD FOUNDATION YXJL-2021-0302-0287The First Affiliated Hospital of Harbin Medical University Fund for Distinguished Young Medical Scholars 2021J17
6 · The paper itself

Abstract

Breast cancer, a heterogeneous disease, is notable for its high morbidity, recurrence, and mortality. T3N0M0 is controversial in terms of clinical prognosis and therapeutic decision-making. We collected baseline and treatment information on patients with T3N0M0 between 2010 and 2015 from the Surveillance, Epidemiology, and End Results programme (SEER) database. Univariate analyses of clinicopathological characteristics were performed using the log-rank test, while variables that were statistically significant (p < 0.05) were included in multivariate analyses to identify prognostic risk factors included in the construction of nomograms. Receiver operating characteristic (ROC) curves, calibration curves and decision curve analysis (DCA) curves were applied to evaluate the nomogram. We obtained a total of 4,641 patient clinical characteristics from the SEER database. In T3N0M0 group, the overall survival (OS) for 3, 5 and 10 years was 87.1%, 79.5% and 71.6%, and breast cancer-specific survival (BCSS) was 92.0%, 88.1% and 85.3%, respectively. We ultimately identified eight variables (age, grade, surgery, radiation, chemotherapy, ER-status, PR-status, Her2-status) were associated with OS while seven variables (age, grade, surgery, radiation, chemotherapy, PR-status, Her2-status) were associated with BCSS. The nomogram was constructed based on independent prognostic risk factors, the area under the curve (AUC) values were well performed, the ROC curves, calibration curves and DCA curves all indicated that the nomogram had better clinical practicability. The current study provides a new clinical assessment tool for T3N0M0 breast cancer patients, as well as a reference for clinicians in selecting management decisions.

Indexed as

Breast NeoplasmsNomogramsAdultAgedFemaleHumansMiddle AgedNeoplasm StagingPrognosisRisk FactorsROC CurveSEER ProgramSurvival AnalysisBreast cancerNomogramSurvivalT3N0M0Treatment

Identifiers

PMID40651990
PMCPMC12255696

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.